• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    AstraZeneca's H1 and Q2 2024 Financial Results

    7/25/24 7:00:00 AM ET
    $AZN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AZN alert in real time by email

    Strong underlying growth supports FY 2024 guidance upgrade, with both Total Revenue and Core EPS now expected to increase by a mid teens percentage at CER1

    AstraZeneca:

    Revenue and EPS summary

    H1 2024

    % Change

     

    Q2 2024

    % Change

    $m

    Actual

    CER

     

    $m

    Actual

    CER

    - Product Sales

    24,629

    15

    18

     

    12,452

    14

    18

    - Alliance Revenue

     

    939

    50

    50

     

    482

    42

    42

    - Collaboration Revenue

    49

    (78)

    (78)

     

    4

    (98)

    (98)

    Total Revenue

     

    25,617

    15

    18

     

    12,938

    13

    17

    Reported EPS

    $2.65

    13

    23

     

    $1.24

    6

    15

    Core2 EPS

    $4.03

    (1)

    5

     

    $1.98

    (8)

    (3)

    Financial performance for H1 2024 (Growth numbers at constant exchange rates)

    • Total Revenue up 18% to $25,617m, driven by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines
    • Total Revenue growth from Oncology was 22%, CVRM 22%, R&I 22%, and Rare Disease 15%
    • Core Product Sales Gross Margin3 of 82%
    • Core Operating Margin of 33%
    • Core Tax Rate of 20%
    • Core EPS increased 5% to $4.03. The increase in Core EPS was lower than Total Revenue growth principally due to gains recognised in the prior year, specifically a $241m gain on the disposal of Pulmicort Flexhaler US rights (Q1 2023), and a $712m gain relating to updates to contractual arrangements for Beyfortus (Q2 2023)
    • Interim dividend increased 7c to $1.00 (77.6 pence, 10.79 SEK) has been declared
    • Guidance for FY 2024 increased, with Total Revenue and Core EPS anticipated to grow by a mid teens percentage at CER (previously a low double-digit to low teens percentage). An increase in Collaboration Revenue is not assumed in the upgraded guidance

    Pascal Soriot, Chief Executive Officer, AstraZeneca, said:

    "Building on our strong growth in the first half of the year and continued underlying demand for our medicines we are upgrading our FY 2024 guidance for both Total Revenue and Core EPS.

    At our Investor Day in May we set out a new revenue ambition to deliver $80 billion of Total Revenue by 2030. This is a clear reflection of the substantial growth potential we see from both our approved medicines and those in our late-stage pipeline. Already this year we have announced five positive, potentially practice-changing Phase III studies that are anticipated to meaningfully contribute to our growth.

    In the year to date we have continued to make encouraging progress with several disruptive technologies, including antibody drug conjugates, bispecifics, cell and gene therapies, radioconjugates, and weight management medicines, all of which have the potential to drive our growth beyond 2030."

    Key milestones achieved since the prior results announcement

    • Positive read-outs for Imfinzi in combination with chemotherapy in muscle-invasive bladder cancer (NIAGARA), Calquence in untreated mantle cell lymphoma (ECHO), Enhertu in HR-positive, HER2-low metastatic breast cancer (DESTINY-Breast06)
    • US approvals for Imfinzi in combination with chemotherapy followed by Imfinzi monotherapy for primary advanced or recurrent endometrial cancer that is mismatch repair deficient (DUO-E). EU approvals for Truqap in combination with Faslodex for biomarker-positive estrogen receptor-positive, HER2‑negative advanced breast cancer (CAPItello-291), Tagrisso with the addition of chemotherapy for 1st‑line EGFRm NSCLC (FLAURA2). Japan and China approvals for Tagrisso with the addition of chemotherapy for the 1st­­‑line EGFRm NSCLC (FLAURA2)

    Guidance

    Due to strong underlying growth in Product Sales and Alliance Revenue, the Company raises its Total Revenue and Core EPS guidance for FY 2024 at CER, based on the average foreign exchange rates through 2023.

     

    Total Revenue is expected to increase by a mid teens percentage

    (previously a low double-digit to low teens percentage)

     

    Core EPS is expected to increase by a mid teens percentage

    (previously a low double-digit to low teens percentage)

     
    • An increase in Collaboration Revenue is not assumed in the upgraded guidance (previously assumed a substantial increase)
    • Other operating income is expected to decrease substantially (FY 2023 included a $241m gain on the disposal of Pulmicort Flexhaler US rights, and a $712m one-time gain relating to updates to contractual arrangements for Beyfortus)
    • The Core Tax rate is expected to be between 18-22%

    The Company is unable to provide guidance on a Reported basis because it cannot reliably forecast material elements of the Reported results, including any fair value adjustments arising on acquisition-related liabilities, intangible asset impairment charges and legal settlement provisions. Please refer to the cautionary statements section regarding forward-looking statements at the end of this announcement.

    Currency impact

    If foreign exchange rates for July 2024 to December 2024 were to remain at the average rates seen in June 2024, it is anticipated that FY 2024 Total Revenue would incur a low single-digit percentage adverse impact compared to the performance at CER, and Core EPS would incur a mid single-digit percentage adverse impact. The Company's foreign exchange rate sensitivity analysis is provided in Table 17.

    Table 1: Key elements of Total Revenue performance in Q2 2024

    % Change

     

    Revenue type

     

    $m

    Actual %

    CER %

     

     

    Product Sales

    12,452

    14

    18

     

     

    Alliance Revenue

    482

    42

    42

    • $344m Enhertu (Q2 2023: $255m)

    • $104m Tezspire (Q2 2023: $62m)

    Collaboration Revenue

    4

    (98)

    (98)

    • Q2 2023 included $180m for COVID-19 mAbs

    Total Revenue

     

    12,938

    13

    17

     

     

    Therapy areas

    $m

    Actual %

    CER %

     

     

    Oncology

    5,331

    15

    19

     

    • Tagrisso up 8% (12% at CER) due to strong global demand, Calquence up 21% (22% at CER) with sustained leadership in 1L CLL. Enhertu Total Revenue up 46% (49% at CER)

    CVRM

    3,160

    18

    22

     

    • Farxiga up 29% (32% at CER), Lokelma up 36% (41% at CER)

    R&I

     

    1,905

    23

    26

     

    • Breztri up 44% (47% at CER). Saphnelo up 65%, Tezspire up 97% (>2x at CER), Symbicort up 20% (25% CER)

    V&I

    119

    (57)

    (53)

    • The drop in V&I revenue was primarily driven by lower Collaboration Revenue from COVID-19 mAbs

    • Beyfortus revenue was $35m (Q2 2023: $2m), which more than offset a $6m decline in Synagis

    Rare Disease

    2,147

    10

    14

    • Ultomiris up 33% (36% at CER), partially offset by decline in Soliris of 14% (8% at CER)

    • Strensiq up 13% (14% at CER) and Koselugo up 43% (45% at CER)

    Other Medicines

     

    276

    (11)

    (5)

     

     

    Total Revenue

     

    12,938

    13

    17

     

     

    Regions

     

    $m

    Actual %

    CER %

     

     

    US

    5,571

    17

    17

     

     

    Emerging Markets

     

    3,386

    9

    18

     

     

    - China

    1,630

    13

    18

     

     

    - Ex-China Emerging Markets

     

    1,756

    5

    18

     

     

    Europe

     

    2,732

    24

    24

     

     

    Established RoW

     

    1,249

    (5)

    6

     

     

    Total Revenue

     

    12,938

    13

    17

     

     

    Key partnered medicines

    • Combined sales of Enhertu, recorded by Daiichi Sankyo Company Limited (Daiichi Sankyo) and AstraZeneca, amounted $1,772m in H1 2024 (H1 2023: $1,169m).
    • Combined sales of Tezspire, recorded by Amgen and AstraZeneca, amounted to $507m in H1 2024 (H1 2023: $257m).

    Table 2: Key elements of financial performance in Q2 2024

    Metric

    Reported

    Reported change

    Core

    Core

    change

     

    Comments4

    Total Revenue

    $12,938m

    13% Actual

    17% CER

    $12,938m

    13% Actual

    17% CER

     

    • See Table 1 and the Total Revenue section of this document for further details

    Product Sales Gross Margin

    82%

    Stable Actual

    Stable CER

    83%

    Stable Actual

    Stable CER

     

    • Variations in Product Sales Gross Margin can be expected between periods due to product seasonality (e.g. FluMist and Beyfortus in H2), foreign exchange fluctuations and other effects

    R&D

    expense

    $3,008m

    13% Actual

    13% CER

    $2,872m

    12% Actual

    13% CER

    + Increased investment in the pipeline

    • Core R&D-to-Total Revenue ratio of 22%

    (Q2 2023: 22%)

    SG&A expense

    $4,929m

    -1% Actual

    1% CER

    $3,735m

    13% Actual

    16% CER

    + Market development for recent launches and pre-launch activities

    • Core SG&A-to-Total Revenue ratio of 29%

    (Q2 2023: 29%)

    Other operating income and expense5

    $60m

    -92% Actual

    -92% CER

    $60m

    -92% Actual

    -92% CER

     

    ‒The prior year quarter included a $712m gain relating to updates to contractual arrangements for Beyfortus

    Operating Margin

    21%

    Stable Actual

    +1pp CER

    32%

    -6pp Actual

    -5pp CER

     

    • See commentary above on Gross Margin, R&D, SG&A and Other operating income and expense

    Net finance expense

    $343m

    -7% Actual

    -7% CER

    $285m

    10% Actual

    10% CER

     

    + Higher level of Net debt

    Tax rate

    20%

    +7pp Actual

    +7pp CER

    19%

    +2pp Actual

    +2pp CER

     

    • Variations in the tax rate can be expected between periods

    EPS

    $1.24

    6% Actual

    15% CER

    $1.98

    -8% Actual

    -3% CER

     

    • Further details of differences between Reported and Core are shown in Table 12

    Table 3: Pipeline highlights since prior results announcement

    Event

    Medicine

    Indication / Trial

     

    Event

    Regulatory approvals and other regulatory actions

    Imfinzi

    Primary advanced or recurrent endometrial cancer with mismatch repair deficiency (DUO-E)

    Regulatory approval (US), CHMP positive opinion (EU)

    Imfinzi + Lynparza

    Primary advanced or recurrent endometrial cancer with mismatch repair proficiency (DUO-E)

    CHMP positive opinion (EU)

    Tagrisso

    EGFRm NSCLC (1st-line)

    (FLAURA2)

    Regulatory approval (EU, JP, CN)

    Truqap

    Biomarker-positive ER-positive HER2-negative locally advanced or metastatic breast cancer (CAPItello-291)

    Regulatory approval (EU)

     

     

     

    Regulatory submissions

    or acceptances*

    Tagrisso

    EGFRm NSCLC (Stage III unresectable) (LAURA)

    sNDA acceptance and Priority Review (US)

    Dato-DXd

     

    Non-squamous NSCLC (2nd- and 3rd-line) (TROPION-Lung01)

    Regulatory submission (EU)

    sipavibart

    Prevention of COVID-19

    (SUPERNOVA)

    Regulatory submission (EU)

     

     

     

    Major Phase III data readouts and other developments

    Calquence

    Mantle cell lymphoma (1st‑line) (ECHO)

    Primary endpoint met

    Dato-DXd

    Locally advanced or metastatic NSCLC (TROPION-Lung01)

    Dual primary endpoint OS not met in the intention to treat population

    Enhertu

    HER2-low breast cancer (2nd-line) (DESTINY-Breast-06)

    Primary endpoint met

    Imfinzi

    Muscle-invasive bladder cancer (NIAGARA)

    Primary endpoint met

    Imfinzi

    Adjuvant use in early-stage PD-L1 ≥25% NSCLC (Adjuvant BR.31)

    Primary endpoint not met

     

     

     

     

     

    Truqap

    Locally advanced or metastatic TNBC (CAPItello-290)

    Primary endpoint not met

     

     

     

     

     

    sipavibart

    Prevention of COVID-19 (SUPERNOVA)

    Primary endpoint met

    *US, EU and China regulatory submission denotes filing acceptance

    Upcoming pipeline catalysts

    For recent trial starts and anticipated timings of key trial readouts, please refer to the Clinical Trials Appendix, available on www.astrazeneca.com/investor-relations.html.

    Corporate and business development

    In May 2024, AstraZeneca announced its intention to build a $1.5 billion manufacturing facility in Singapore for antibody drug conjugates (ADCs), enhancing global supply of its ADC portfolio. ADCs are next-generation treatments that deliver highly potent cancer-killing agents directly to cancer cells through a targeted antibody. The planned greenfield facility, supported by the Singapore Economic Development Board, will be AstraZeneca's first end-to-end ADC production site, fully incorporating all steps of the manufacturing process at a commercial scale. Manufacturing of ADCs is a multi-step process that comprises antibody production, synthesis of chemotherapy drug and linker, conjugation of drug-linker to the antibody, and filling of the completed ADC substance.

    In May 2024, AstraZeneca completed an additional $140m equity investment in Cellectis, a clinical-stage biotechnology company. The equity investment and a research collaboration agreement, announced in November 2023, will leverage the Cellectis proprietary gene editing technologies and manufacturing capabilities, to design up to 10 novel cell and gene therapy products for areas of high unmet need, including oncology, immunology and rare diseases. In Q4 2023, Cellectis received an initial payment of $105m from AstraZeneca, which comprised a $25m upfront cash payment under the terms of a research collaboration agreement and an $80m equity investment. Now that the additional $140m equity investment has closed, AstraZeneca holds a total equity stake of c.44% in Cellectis and AstraZeneca continues to treat its investment in Cellectis as an associate.

    In June 2024, AstraZeneca completed the acquisition of Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company developing next-generation radioconjugates. The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments. The acquisition complements AstraZeneca's leading oncology portfolio with the addition of the Fusion pipeline of radioconjugates, including FPI-2265, a potential new treatment for patients with mCRPC, and brings new expertise and pioneering R&D, manufacturing and supply chain capabilities in actinium-based radioconjugates to AstraZeneca. See Note 5 for further information.

    In July 2024, AstraZeneca completed the acquisition of Amolyt Pharma, a clinical-stage biotechnology company focused on developing novel treatments for rare endocrine diseases. The acquisition bolsters the Alexion, AstraZeneca Rare Disease late-stage pipeline and expands on its bone metabolism franchise with the notable addition of eneboparatide (AZP-3601), a Phase III investigational therapeutic peptide with a novel mechanism of action designed to meet key therapeutic goals for hypoparathyroidism. In patients with hypoparathyroidism, a deficiency in parathyroid hormone production results in significant dysregulation of calcium and phosphate, which can lead to life-altering symptoms and complications, including chronic kidney disease. See Note 7 for further information.

    Sustainability highlights

    At the 77th World Health Assembly in Geneva, Switzerland in May, AstraZeneca convened Ministers of Health, industry, civil society and patient groups. Areas of focus for engagement, led by Ruud Dobber, EVP BioPharmaceuticals, included the need to increase early action to prevent, diagnose and treat disease and to accelerate collaboration to build resilient, equitable and net zero health systems.

    Conference call

    A conference call and webcast for investors and analysts will begin today, 25 July 2024, at 11:45 UK time. Details can be accessed via astrazeneca.com.

    Reporting calendar

    The Company intends to publish its 9M and Q3 2024 results on 12 November 2024.

    To read AstraZeneca's H1 and Q2 2024 Financial Results press release in full including the glossary, please click here.

     

    1

    Constant exchange rates. The differences between Actual Change and CER Change are due to foreign exchange movements between periods in 2024 vs. 2023. CER financial measures are not accounted for according to generally accepted accounting principles (GAAP) because they remove the effects of currency movements from Reported results.

    2

    Core financial measures are adjusted to exclude certain items. The differences between Reported and Core measures are primarily due to costs relating to the amortisation of intangibles, impairments, legal settlements and restructuring charges. A full reconciliation between Reported EPS and Core EPS is provided in Table 11 and Table 12 in the Financial performance section of this document.

    3

    The calculations for Reported and Core Product Sales Gross Margin exclude the impact of Alliance Revenue and Collaboration Revenue.

    4

    In Table 2, the plus and minus symbols denote the directional impact of the item being discussed, e.g. a ‘+' symbol next to a comment related to the R&D expense indicates that the item resulted in an increase in the R&D spend relative to the prior year.

    5

    Income from disposals of assets and businesses, where the Group does not retain a significant ongoing economic interest, continue to be recorded in Other operating income and expense in the Company's financial statements.

     

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240724980001/en/

    Get the next $AZN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AZN

    DatePrice TargetRatingAnalyst
    4/15/2025$75.00Outperform
    Exane BNP Paribas
    2/13/2025Neutral → Buy
    UBS
    2/12/2025Overweight
    Morgan Stanley
    11/20/2024Sell → Neutral
    UBS
    11/6/2024Sell → Hold
    Deutsche Bank
    9/13/2024Hold → Sell
    Deutsche Bank
    5/30/2024$97.00Buy
    Goldman
    4/16/2024Sell → Hold
    Deutsche Bank
    More analyst ratings

    $AZN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • IMFINZI® (durvalumab) regimen demonstrated statistically significant and clinically meaningful improvement in disease-free survival for high-risk non-muscle-invasive bladder cancer in POTOMAC Phase III trial

      Patients lived significantly longer without high-risk disease recurrence or progression after one year of IMFINZI treatment plus Bacillus Calmette-Guérin (BCG) induction and maintenance therapy vs. BCG alone Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.​ The trial was not statistically powered to formally test ov

      5/9/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11

      AstraZeneca and Daiichi Sankyo's ENHERTU followed by THP showed an improved safety profile vs. standard of care First Phase III trial to demonstrate benefit of ENHERTU in early breast cancer Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positi

      5/7/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial

      Daiichi Sankyo and AstraZeneca's ENHERTU followed by THP showed an improved safety profile versus standard of care First phase 3 trial to demonstrate benefit of ENHERTU in early breast cancer Results will be shared with regulatory authorities Positive topline results from the DESTINY-Breast11 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients w

      5/7/25 2:30:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Financials

    Live finance-specific insights

    See more
    • AstraZeneca's Q1 2025 Financial Results

      Growth momentum and pipeline delivery set AstraZeneca on a strong trajectory towards 2030 ambition AstraZeneca: Revenue and EPS summary   Q1 2025 % Change       $m Actual CER1       - Product Sales 12,875 6 9       - Alliance Revenue 639 40 42       Product Revenue2 13,514 7 10       Collaboration Revenue 74 64 64       Total Revenue 13,588 7 10       Reported EPS ($) 1.88 34 32       Core3 EPS ($) 2.49 21 21       Key performance elements for Q1 2025 (Growth numbers at constant exchange

      4/29/25 2:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • AstraZeneca's Full Year and Q4 2024 results

      Strong momentum in FY 2024 with Total Revenue and Core EPS up 21% and 19% respectively AstraZeneca: Revenue and EPS summary     FY 2024 % Change Q4 2024 % Change $m Actual CERi $m Actual CER - Product Sales 50,938 16 19 13,362 18 19 - Alliance Revenue   2,212 55 55 714 68 69 - Collaboration Revenue 923 56 54 815 >2x >2x Total Revenue   54,073 18 21 14,891 24 25 Reported EPS $4.54 18 29

      2/6/25 7:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Leadership Updates

    Live Leadership Updates

    See more
    • I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ:IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced the appointment of Dr. Phillip Dennis as Chief Medical Officer. Dr. Dennis, who will join I-Mab effective June 17, 2024, will lead the Company's global clinical development efforts and serve as a member of I-Mab's Executive Leadership Team. "I am pleased to welcome Dr. Phillip Dennis as our Chief Medical

      6/6/24 7:00:00 AM ET
      $AZN
      $IMAB
      $SNY
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Alexion Canada Raises Awareness for Rare Diseases Through International colourUp4RARE Campaign

      In recognition of Rare Disease Day on February 29, Alexion welcomes people across the country to join the international colourUp4RARE challenge and learn more about the impact of rare diseases on an estimated three million Canadian families MISSISSAUGA, ON, Feb. 26, 2024 /CNW/ - Alexion Pharma Canada Corp., AstraZeneca's Rare Disease group, is marking Rare Disease Day on February 29 by launching colourUp4RARE. The international campaign aims to raise awareness of how to improve quality of life of people living with rare diseases in Canada, and around the world. Approximately,

      2/26/24 9:00:00 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

      NIH data show that globally less than 2% of genetic information being studied today originates from people of African ancestry1 The newly established Diaspora Human Genomics Institute (DHGI) will manage the Together for CHANGE initiative, which aims to increase available genomic data for people of African ancestry and enhance representation in STEM careers NASHVILLE, Tenn. and TARRYTOWN, N.Y. and WILMINGTON, Del. and BAGSVAERD, Denmark and BASEL, Switzerland, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Meharry Medical College, along with partners Regeneron Genetics Center® (RGC™), AstraZeneca, Novo Nordisk, and Roche, today announced the launch of the Together for CHANGE™ ("Changing Healthcare for

      10/18/23 9:00:00 AM ET
      $AZN
      $REGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by AstraZeneca PLC (Amendment)

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/4/22 9:06:48 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - ASTRAZENECA PLC (0000901832) (Subject)

      2/3/21 1:13:21 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AZN
    SEC Filings

    See more

    $AZN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/9/25 11:23:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/7/25 9:53:18 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by AstraZeneca PLC

      6-K - ASTRAZENECA PLC (0000901832) (Filer)

      5/6/25 9:15:27 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Exane BNP Paribas initiated coverage on AstraZeneca with a new price target

      Exane BNP Paribas initiated coverage of AstraZeneca with a rating of Outperform and set a new price target of $75.00

      4/15/25 12:40:56 PM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AstraZeneca upgraded by UBS

      UBS upgraded AstraZeneca from Neutral to Buy

      2/13/25 8:39:12 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Morgan Stanley initiated coverage on AstraZeneca

      Morgan Stanley initiated coverage of AstraZeneca with a rating of Overweight

      2/12/25 6:59:42 AM ET
      $AZN
      Biotechnology: Pharmaceutical Preparations
      Health Care